AU2006228150B2 - Inhibitors of neurotrypsin and determination thereof - Google Patents

Info

Publication number

AU2006228150B2

AU2006228150B2 AU2006228150A AU2006228150A AU2006228150B2 AU 2006228150 B2 AU2006228150 B2 AU 2006228150B2 AU 2006228150 A AU2006228150 A AU 2006228150A AU 2006228150 A AU2006228150 A AU 2006228150A AU 2006228150 B2 AU2006228150 B2 AU 2006228150B2

Authority

AU

Australia

Prior art keywords

neurotrypsin

agrin

fragment

cleavage

protein

Prior art date

2005-03-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 108010037733 neurotrypsin Proteins 0.000 title abstract description 324
• 102100035484 Neurotrypsin Human genes 0.000 title abstract description 321
• 239000003112 inhibitor Substances 0.000 title abstract description 30
• 101150079978 AGRN gene Proteins 0.000 claims abstract description 249
• 108700019743 Agrin Proteins 0.000 claims abstract description 249
• 102100040026 Agrin Human genes 0.000 claims abstract description 247
• 238000003776 cleavage reaction Methods 0.000 claims abstract description 157
• 230000007017 scission Effects 0.000 claims abstract description 154
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 92
• 239000012634 fragment Substances 0.000 claims abstract description 89
• 102000004169 proteins and genes Human genes 0.000 claims abstract description 89
• 238000000034 method Methods 0.000 claims abstract description 56
• 108091005804 Peptidases Proteins 0.000 claims abstract description 34
• 239000004365 Protease Substances 0.000 claims abstract description 32
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 3
• 101001023733 Homo sapiens Neurotrypsin Proteins 0.000 claims description 28
• 150000001413 amino acids Chemical class 0.000 claims description 27
• 238000001514 detection method Methods 0.000 claims description 22
• 108091035707 Consensus sequence Proteins 0.000 claims description 7
• 108020001507 fusion proteins Proteins 0.000 claims description 6
• 102000037865 fusion proteins Human genes 0.000 claims description 6
• 239000003550 marker Substances 0.000 claims description 6
• 108010000845 C-terminal agrin fragment Proteins 0.000 claims description 5
• 210000000225 synapse Anatomy 0.000 abstract description 74
• 150000001875 compounds Chemical class 0.000 abstract description 55
• 201000000980 schizophrenia Diseases 0.000 abstract description 35
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 27
• 208000026214 Skeletal muscle atrophy Diseases 0.000 abstract description 20
• 230000025185 skeletal muscle atrophy Effects 0.000 abstract description 20
• 239000000243 solution Substances 0.000 abstract description 18
• 238000011282 treatment Methods 0.000 abstract description 18
• 201000010099 disease Diseases 0.000 abstract description 17
• 208000010877 cognitive disease Diseases 0.000 abstract description 15
• 238000011321 prophylaxis Methods 0.000 abstract description 8
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract description 6
• 229940100584 Neurotrypsin inhibitor Drugs 0.000 abstract description 6
• 239000012062 aqueous buffer Substances 0.000 abstract description 6
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract description 6
• 229910052794 bromium Inorganic materials 0.000 abstract description 6
• 230000007812 deficiency Effects 0.000 abstract description 6
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract description 4
• 239000000460 chlorine Substances 0.000 abstract description 4
• 229910052801 chlorine Inorganic materials 0.000 abstract description 4
• 229910052731 fluorine Inorganic materials 0.000 abstract description 4
• 239000011737 fluorine Substances 0.000 abstract description 4
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 105
• 210000004027 cell Anatomy 0.000 description 103
• 241000699670 Mus sp. Species 0.000 description 92
• 235000018102 proteins Nutrition 0.000 description 81
• 235000002639 sodium chloride Nutrition 0.000 description 63
• 230000000946 synaptic effect Effects 0.000 description 60
• 239000000758 substrate Substances 0.000 description 58
• 210000004899 c-terminal region Anatomy 0.000 description 52
• 239000011780 sodium chloride Substances 0.000 description 52
• 210000000715 neuromuscular junction Anatomy 0.000 description 50
• 230000000694 effects Effects 0.000 description 45
• 210000002161 motor neuron Anatomy 0.000 description 44
• 210000003169 central nervous system Anatomy 0.000 description 43
• 230000014509 gene expression Effects 0.000 description 38
• 238000001262 western blot Methods 0.000 description 35
• 238000011830 transgenic mouse model Methods 0.000 description 33
• 102000035195 Peptidases Human genes 0.000 description 31
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
• 241000699660 Mus musculus Species 0.000 description 28
• 210000003205 muscle Anatomy 0.000 description 28
• 210000002569 neuron Anatomy 0.000 description 28
• 239000000047 product Substances 0.000 description 27
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 26
• 238000003556 assay Methods 0.000 description 26
• 230000002018 overexpression Effects 0.000 description 26
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 26
• 210000001087 myotubule Anatomy 0.000 description 25
• 230000009467 reduction Effects 0.000 description 25
• 239000002609 medium Substances 0.000 description 24
• 230000001242 postsynaptic effect Effects 0.000 description 24
• 235000019419 proteases Nutrition 0.000 description 24
• 239000006228 supernatant Substances 0.000 description 22
• 230000001965 increasing effect Effects 0.000 description 21
• 230000005764 inhibitory process Effects 0.000 description 21
• 235000001014 amino acid Nutrition 0.000 description 20
• 229940024606 amino acid Drugs 0.000 description 20
• 239000012528 membrane Substances 0.000 description 20
• 230000002829 reductive effect Effects 0.000 description 20
• 230000002797 proteolythic effect Effects 0.000 description 19
• -1 20 factor XIla Proteins 0.000 description 18
• 241000699666 Mus <mouse, genus> Species 0.000 description 18
• 230000003197 catalytic effect Effects 0.000 description 18
• 239000007993 MOPS buffer Substances 0.000 description 17
• 101001023737 Mus musculus Neurotrypsin Proteins 0.000 description 17
• 210000002027 skeletal muscle Anatomy 0.000 description 17
• 210000000278 spinal cord Anatomy 0.000 description 17
• 108700019146 Transgenes Proteins 0.000 description 16
• 238000006243 chemical reaction Methods 0.000 description 16
• 238000001727 in vivo Methods 0.000 description 16
• 230000002401 inhibitory effect Effects 0.000 description 16
• 210000001519 tissue Anatomy 0.000 description 15
• 238000001890 transfection Methods 0.000 description 15
• 108010051219 Cre recombinase Proteins 0.000 description 14
• 238000011534 incubation Methods 0.000 description 14
• 238000004519 manufacturing process Methods 0.000 description 14
• 239000008363 phosphate buffer Substances 0.000 description 14
• 239000013598 vector Substances 0.000 description 14
• 241000282414 Homo sapiens Species 0.000 description 13
• 210000004556 brain Anatomy 0.000 description 13
• 239000003795 chemical substances by application Substances 0.000 description 13
• 230000003920 cognitive function Effects 0.000 description 13
• 230000006870 function Effects 0.000 description 13
• 230000003518 presynaptic effect Effects 0.000 description 13
• 230000009261 transgenic effect Effects 0.000 description 13
• 206010035226 Plasma cell myeloma Diseases 0.000 description 12
• 239000000872 buffer Substances 0.000 description 12
• 201000000050 myeloid neoplasm Diseases 0.000 description 12
• 238000010186 staining Methods 0.000 description 12
• RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 11
• 108020004414 DNA Proteins 0.000 description 11
• 101150104007 NTM gene Proteins 0.000 description 11
• 239000003814 drug Substances 0.000 description 11
• 239000000203 mixture Substances 0.000 description 11
• 210000001938 protoplast Anatomy 0.000 description 11
• 238000000746 purification Methods 0.000 description 11
• 150000003839 salts Chemical class 0.000 description 11
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
• 238000004458 analytical method Methods 0.000 description 10
• 230000001419 dependent effect Effects 0.000 description 10
• 208000035475 disorder Diseases 0.000 description 10
• 108010048367 enhanced green fluorescent protein Proteins 0.000 description 10
• 239000000284 extract Substances 0.000 description 10
• 239000000499 gel Substances 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 239000008118 PEG 6000 Substances 0.000 description 9
• 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 9
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
• 238000004587 chromatography analysis Methods 0.000 description 9
• 238000010828 elution Methods 0.000 description 9
• 239000000835 fiber Substances 0.000 description 9
• 238000013467 fragmentation Methods 0.000 description 9
• 238000006062 fragmentation reaction Methods 0.000 description 9
• 239000000523 sample Substances 0.000 description 9
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
• 108010088842 Fibrinolysin Proteins 0.000 description 8
• 239000007995 HEPES buffer Substances 0.000 description 8
• 102000012479 Serine Proteases Human genes 0.000 description 8
• 108010022999 Serine Proteases Proteins 0.000 description 8
• 101150052863 THY1 gene Proteins 0.000 description 8
• 108090000190 Thrombin Proteins 0.000 description 8
• 101150036876 cre gene Proteins 0.000 description 8
• 239000008194 pharmaceutical composition Substances 0.000 description 8
• 229940012957 plasmin Drugs 0.000 description 8
• 238000013138 pruning Methods 0.000 description 8
• 229940124530 sulfonamide Drugs 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 229960004072 thrombin Drugs 0.000 description 8
• 206010003694 Atrophy Diseases 0.000 description 7
• 206010012289 Dementia Diseases 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 108010076504 Protein Sorting Signals Proteins 0.000 description 7
• 108090000631 Trypsin Proteins 0.000 description 7
• 102000004142 Trypsin Human genes 0.000 description 7
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 7
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 7
• 239000004480 active ingredient Substances 0.000 description 7
• 238000001042 affinity chromatography Methods 0.000 description 7
• 230000037444 atrophy Effects 0.000 description 7
• 210000004900 c-terminal fragment Anatomy 0.000 description 7
• 230000003247 decreasing effect Effects 0.000 description 7
• 210000003520 dendritic spine Anatomy 0.000 description 7
• 229940088598 enzyme Drugs 0.000 description 7
• 238000002474 experimental method Methods 0.000 description 7
• 239000001963 growth medium Substances 0.000 description 7
• 238000013537 high throughput screening Methods 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 230000015654 memory Effects 0.000 description 7
• 210000000063 presynaptic terminal Anatomy 0.000 description 7
• 239000012588 trypsin Substances 0.000 description 7
• 229960005356 urokinase Drugs 0.000 description 7
• 238000012800 visualization Methods 0.000 description 7
• 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 6
• 208000002109 Argyria Diseases 0.000 description 6
• 241000287828 Gallus gallus Species 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 101000916423 Homo sapiens Calsyntenin-1 Proteins 0.000 description 6
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• 102000003992 Peroxidases Human genes 0.000 description 6
• 101000959590 Rattus norvegicus Agrin Proteins 0.000 description 6
• 229920002684 Sepharose Polymers 0.000 description 6
• 230000006866 deterioration Effects 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 6
• 210000004884 grey matter Anatomy 0.000 description 6
• 229960002897 heparin Drugs 0.000 description 6
• 229920000669 heparin Polymers 0.000 description 6
• 210000001320 hippocampus Anatomy 0.000 description 6
• 102000050584 human CLSTN1 Human genes 0.000 description 6
• 230000003053 immunization Effects 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 108040007629 peroxidase activity proteins Proteins 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 230000000698 schizophrenic effect Effects 0.000 description 6
• 230000002103 transcriptional effect Effects 0.000 description 6
• 239000003656 tris buffered saline Substances 0.000 description 6
• 208000024827 Alzheimer disease Diseases 0.000 description 5
• 239000004475 Arginine Substances 0.000 description 5
• 108091026890 Coding region Proteins 0.000 description 5
• 241000701022 Cytomegalovirus Species 0.000 description 5
• 108060005987 Kallikrein Proteins 0.000 description 5
• 102000001399 Kallikrein Human genes 0.000 description 5
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
• 239000004472 Lysine Substances 0.000 description 5
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
• 235000004279 alanine Nutrition 0.000 description 5
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
• 230000009286 beneficial effect Effects 0.000 description 5
• 239000001506 calcium phosphate Substances 0.000 description 5
• 230000015556 catabolic process Effects 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 239000002475 cognitive enhancer Substances 0.000 description 5
• 230000006735 deficit Effects 0.000 description 5
• 238000006731 degradation reaction Methods 0.000 description 5
• 230000004927 fusion Effects 0.000 description 5
• 238000001597 immobilized metal affinity chromatography Methods 0.000 description 5
• 238000002649 immunization Methods 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 230000004807 localization Effects 0.000 description 5
• 230000003387 muscular Effects 0.000 description 5
• 201000000585 muscular atrophy Diseases 0.000 description 5
• 230000001537 neural effect Effects 0.000 description 5
• 210000004179 neuropil Anatomy 0.000 description 5
• 229910052757 nitrogen Inorganic materials 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 238000011002 quantification Methods 0.000 description 5
• 208000001076 sarcopenia Diseases 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 230000003977 synaptic function Effects 0.000 description 5
• 230000002123 temporal effect Effects 0.000 description 5
• 230000007704 transition Effects 0.000 description 5
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
• 241000271566 Aves Species 0.000 description 4
• 241000283707 Capra Species 0.000 description 4
• 108010009685 Cholinergic Receptors Proteins 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• 108010074860 Factor Xa Proteins 0.000 description 4
• ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 4
• ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 4
• 206010028289 Muscle atrophy Diseases 0.000 description 4
• BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 description 4
• 229930040373 Paraformaldehyde Natural products 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 239000007983 Tris buffer Substances 0.000 description 4
• 102000034337 acetylcholine receptors Human genes 0.000 description 4
• 230000006978 adaptation Effects 0.000 description 4
• 230000032683 aging Effects 0.000 description 4
• 230000004075 alteration Effects 0.000 description 4
• 239000012131 assay buffer Substances 0.000 description 4
• BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 description 4
• 235000011010 calcium phosphates Nutrition 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 238000010367 cloning Methods 0.000 description 4
• 230000001149 cognitive effect Effects 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 239000003636 conditioned culture medium Substances 0.000 description 4
• 210000001787 dendrite Anatomy 0.000 description 4
• 230000002638 denervation Effects 0.000 description 4
• 230000008034 disappearance Effects 0.000 description 4
• 230000008482 dysregulation Effects 0.000 description 4
• 230000005284 excitation Effects 0.000 description 4
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
• 230000013632 homeostatic process Effects 0.000 description 4
• 238000012744 immunostaining Methods 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 238000004255 ion exchange chromatography Methods 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 208000027061 mild cognitive impairment Diseases 0.000 description 4
• 230000000877 morphologic effect Effects 0.000 description 4
• 210000000653 nervous system Anatomy 0.000 description 4
• 229920002866 paraformaldehyde Polymers 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 239000008188 pellet Substances 0.000 description 4
• 210000001428 peripheral nervous system Anatomy 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 230000006798 recombination Effects 0.000 description 4
• 238000005215 recombination Methods 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 229960004793 sucrose Drugs 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• 230000034365 zymogen activation Effects 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 108090000317 Chymotrypsin Proteins 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
• 239000000020 Nitrocellulose Substances 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 241000700157 Rattus norvegicus Species 0.000 description 3
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 239000006180 TBST buffer Substances 0.000 description 3
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 150000001409 amidines Chemical group 0.000 description 3
• 210000004960 anterior grey column Anatomy 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 239000007853 buffer solution Substances 0.000 description 3
• 229960001714 calcium phosphate Drugs 0.000 description 3
• 229910000389 calcium phosphate Inorganic materials 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 239000001768 carboxy methyl cellulose Substances 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 210000003710 cerebral cortex Anatomy 0.000 description 3
• 229960002376 chymotrypsin Drugs 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000012228 culture supernatant Substances 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 239000003599 detergent Substances 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 239000013604 expression vector Substances 0.000 description 3
• 239000000834 fixative Substances 0.000 description 3
• 230000009760 functional impairment Effects 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 208000014674 injury Diseases 0.000 description 3
• 150000002500 ions Chemical class 0.000 description 3
• 125000005647 linker group Chemical group 0.000 description 3
• 238000011068 loading method Methods 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 230000037323 metabolic rate Effects 0.000 description 3
• 210000005036 nerve Anatomy 0.000 description 3
• 239000002858 neurotransmitter agent Substances 0.000 description 3
• 229920001220 nitrocellulos Polymers 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 208000022821 personality disease Diseases 0.000 description 3
• OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 210000001176 projection neuron Anatomy 0.000 description 3
• 238000010791 quenching Methods 0.000 description 3
• 230000000171 quenching effect Effects 0.000 description 3
• 239000011541 reaction mixture Substances 0.000 description 3
• 108091008146 restriction endonucleases Proteins 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 239000010979 ruby Substances 0.000 description 3
• 229910001750 ruby Inorganic materials 0.000 description 3
• 108091005725 scavenger receptor cysteine-rich superfamily Proteins 0.000 description 3
• 239000003001 serine protease inhibitor Substances 0.000 description 3
• 229910052709 silver Inorganic materials 0.000 description 3
• 239000004332 silver Substances 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 238000003153 stable transfection Methods 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 238000005728 strengthening Methods 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 230000003827 upregulation Effects 0.000 description 3
• HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 2
• NYALHJNFWVHYHK-UHFFFAOYSA-N 4-[(3,5-dibromo-2-hydroxyphenyl)methylideneamino]-1-sulfamoylcyclohexa-2,4-diene-1-carboximidamide Chemical compound C(N)(=N)C1(S(=O)(=O)N)CC=C(C=C1)N=CC=1C(O)=C(C=C(C=1)Br)Br NYALHJNFWVHYHK-UHFFFAOYSA-N 0.000 description 2
• TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 208000028698 Cognitive impairment Diseases 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 208000036119 Frailty Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
• 206010019196 Head injury Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 102000029749 Microtubule Human genes 0.000 description 2
• 108091022875 Microtubule Proteins 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 101100517376 Mus musculus Ntm gene Proteins 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• 101100422265 Patiria pectinifera SRCR1 gene Proteins 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 208000028017 Psychotic disease Diseases 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 230000003044 adaptive effect Effects 0.000 description 2
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 229960000723 ampicillin Drugs 0.000 description 2
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
• 238000005571 anion exchange chromatography Methods 0.000 description 2
• RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 2
• 206010003549 asthenia Diseases 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 230000023555 blood coagulation Effects 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 230000037182 bone density Effects 0.000 description 2
• 230000003925 brain function Effects 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 229960005091 chloramphenicol Drugs 0.000 description 2
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
• 239000003593 chromogenic compound Substances 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 238000004891 communication Methods 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
• 239000010949 copper Substances 0.000 description 2
• GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 2
• 108010082025 cyan fluorescent protein Proteins 0.000 description 2
• 230000002354 daily effect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 230000003292 diminished effect Effects 0.000 description 2
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 230000009088 enzymatic function Effects 0.000 description 2
• 239000006167 equilibration buffer Substances 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 108091006047 fluorescent proteins Proteins 0.000 description 2
• 102000034287 fluorescent proteins Human genes 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 230000005021 gait Effects 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 238000002523 gelfiltration Methods 0.000 description 2
• 239000005090 green fluorescent protein Substances 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 238000012203 high throughput assay Methods 0.000 description 2
• 230000000971 hippocampal effect Effects 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
• 230000001969 hypertrophic effect Effects 0.000 description 2
• 238000007901 in situ hybridization Methods 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000007689 inspection Methods 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 238000001638 lipofection Methods 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 210000004688 microtubule Anatomy 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 210000003470 mitochondria Anatomy 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 230000020763 muscle atrophy Effects 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 2
• XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 230000002232 neuromuscular Effects 0.000 description 2
• BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
• WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 150000002894 organic compounds Chemical class 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
• WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 239000011148 porous material Substances 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 108020001580 protein domains Proteins 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 210000002763 pyramidal cell Anatomy 0.000 description 2
• 230000035484 reaction time Effects 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 239000012723 sample buffer Substances 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 238000002864 sequence alignment Methods 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 235000010356 sorbitol Nutrition 0.000 description 2
• 230000010473 stable expression Effects 0.000 description 2
• 238000007447 staining method Methods 0.000 description 2
• TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000002511 suppository base Substances 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000010474 transient expression Effects 0.000 description 2
• 230000014616 translation Effects 0.000 description 2
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
• AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
• LGKDEBYYRWXEDL-UHFFFAOYSA-N 2-aminobenzenecarboximidamide Chemical compound NC(=N)C1=CC=CC=C1N LGKDEBYYRWXEDL-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
• JDQDSEVNMTYMOC-UHFFFAOYSA-N 3-methylbenzenesulfonic acid Chemical compound CC1=CC=CC(S(O)(=O)=O)=C1 JDQDSEVNMTYMOC-UHFFFAOYSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
• HGJPJLDDSHYDAY-UHFFFAOYSA-N 4-chlorocyclohex-4-ene-1,2-dicarboxylic acid Chemical compound OC(=O)C1CC=C(Cl)CC1C(O)=O HGJPJLDDSHYDAY-UHFFFAOYSA-N 0.000 description 1
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 102000004400 Aminopeptidases Human genes 0.000 description 1
• 108090000915 Aminopeptidases Proteins 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• 239000012617 Butyl Sepharose™ 4 Fast Flow Substances 0.000 description 1
• 241000208199 Buxus sempervirens Species 0.000 description 1
• RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 102100022641 Coagulation factor IX Human genes 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 206010010144 Completed suicide Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
• 206010012559 Developmental delay Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 102000012545 EGF-like domains Human genes 0.000 description 1
• 108050002150 EGF-like domains Proteins 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 102000005593 Endopeptidases Human genes 0.000 description 1
• 108010059378 Endopeptidases Proteins 0.000 description 1
• 241000702191 Escherichia virus P1 Species 0.000 description 1
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
• KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 108010091443 Exopeptidases Proteins 0.000 description 1
• 102000018389 Exopeptidases Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010076282 Factor IX Proteins 0.000 description 1
• 108010048049 Factor IXa Proteins 0.000 description 1
• 108010014173 Factor X Proteins 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000006173 Good's buffer Substances 0.000 description 1
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101000959594 Homo sapiens Agrin Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010058683 Immobilized Proteins Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 239000006142 Luria-Bertani Agar Substances 0.000 description 1
• 239000006137 Luria-Bertani broth Substances 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 108090000143 Mouse Proteins Proteins 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• 230000004988 N-glycosylation Effects 0.000 description 1
• 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
• 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 239000002033 PVDF binder Substances 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 108090000113 Plasma Kallikrein Proteins 0.000 description 1
• 102100034869 Plasma kallikrein Human genes 0.000 description 1
• 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
• 101710180012 Protease 7 Proteins 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 101100431670 Rattus norvegicus Ybx3 gene Proteins 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 102000013275 Somatomedins Human genes 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 239000012505 Superdex™ Substances 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 244000098338 Triticum aestivum Species 0.000 description 1
• 108060005989 Tryptase Proteins 0.000 description 1
• 102000001400 Tryptase Human genes 0.000 description 1
• 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
• 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
• COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• YDAFJDAEPUHFIH-HYYMDVBZSA-N [(2r,3r,4r,5r)-5-[6-[(4-amino-4-oxobutyl)amino]purin-9-yl]-3,4-di(propanoyloxy)oxolan-2-yl]methyl propanoate Chemical compound CCC(=O)O[C@@H]1[C@H](OC(=O)CC)[C@@H](COC(=O)CC)O[C@H]1N1C2=NC=NC(NCCCC(N)=O)=C2N=C1 YDAFJDAEPUHFIH-HYYMDVBZSA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
• 229960004373 acetylcholine Drugs 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
• 239000001361 adipic acid Substances 0.000 description 1
• 235000011037 adipic acid Nutrition 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 229960004909 aminosalicylic acid Drugs 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 210000004727 amygdala Anatomy 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000012742 biochemical analysis Methods 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 108020001778 catalytic domains Proteins 0.000 description 1
• 210000005056 cell body Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 238000011210 chromatographic step Methods 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 230000007278 cognition impairment Effects 0.000 description 1
• 230000006999 cognitive decline Effects 0.000 description 1
• 230000037410 cognitive enhancement Effects 0.000 description 1
• 230000002301 combined effect Effects 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000006957 competitive inhibition Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 238000006482 condensation reaction Methods 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000009295 crossflow filtration Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 238000013480 data collection Methods 0.000 description 1
• 230000000593 degrading effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 239000010432 diamond Substances 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• 235000013681 dietary sucrose Nutrition 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 239000004847 durcupan Substances 0.000 description 1
• 238000000635 electron micrograph Methods 0.000 description 1
• 238000010218 electron microscopic analysis Methods 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000003372 electrophysiological method Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 229940066758 endopeptidases Drugs 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 description 1
• SIVVHUQWDOGLJN-UHFFFAOYSA-N ethylsulfamic acid Chemical group CCNS(O)(=O)=O SIVVHUQWDOGLJN-UHFFFAOYSA-N 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 230000008622 extracellular signaling Effects 0.000 description 1
• 229960004222 factor ix Drugs 0.000 description 1
• 229940012426 factor x Drugs 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• 230000035558 fertility Effects 0.000 description 1
• 239000003527 fibrinolytic agent Substances 0.000 description 1
• 230000003480 fibrinolytic effect Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 230000005484 gravity Effects 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 210000001879 hippocampal ca1 region Anatomy 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 230000003284 homeostatic effect Effects 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 238000005286 illumination Methods 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000010365 information processing Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000030214 innervation Effects 0.000 description 1
• 150000002484 inorganic compounds Chemical class 0.000 description 1
• 229910010272 inorganic material Inorganic materials 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 210000003125 jurkat cell Anatomy 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 230000008449 language Effects 0.000 description 1
• 238000011031 large-scale manufacturing process Methods 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000012160 loading buffer Substances 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 230000006386 memory function Effects 0.000 description 1
• 206010027175 memory impairment Diseases 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 229960002900 methylcellulose Drugs 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• 238000001000 micrograph Methods 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 108091005763 multidomain proteins Proteins 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 230000004118 muscle contraction Effects 0.000 description 1
• QQVNCBCBFNWLJX-KCHLEUMXSA-N n-[(2s)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]benzamide Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)NC(=O)C=1C=CC=CC=1)C1=CC=CC=C1 QQVNCBCBFNWLJX-KCHLEUMXSA-N 0.000 description 1
• 210000004898 n-terminal fragment Anatomy 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 239000006225 natural substrate Substances 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 230000003767 neural control Effects 0.000 description 1
• 230000003988 neural development Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000007970 neurodevelopmental deficit Effects 0.000 description 1
• 230000003955 neuronal function Effects 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 108010032563 oligopeptidase Proteins 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 239000012285 osmium tetroxide Substances 0.000 description 1
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000011164 ossification Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• 108010085336 phosphoribosyl-AMP cyclohydrolase Proteins 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
• 230000007542 postnatal development Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229940116317 potato starch Drugs 0.000 description 1
• 238000011533 pre-incubation Methods 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 210000002442 prefrontal cortex Anatomy 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 235000012434 pretzels Nutrition 0.000 description 1
• 230000007425 progressive decline Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• HLIBNTOXKQCYMV-UHFFFAOYSA-N propylsulfamic acid Chemical compound CCCNS(O)(=O)=O HLIBNTOXKQCYMV-UHFFFAOYSA-N 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 239000011546 protein dye Substances 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000007832 reinnervation Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 210000003660 reticulum Anatomy 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 229940100486 rice starch Drugs 0.000 description 1
• 230000000630 rising effect Effects 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 108010059841 serine carboxypeptidase Proteins 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 208000037974 severe injury Diseases 0.000 description 1
• 230000009528 severe injury Effects 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000008054 signal transmission Effects 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 230000003997 social interaction Effects 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 230000007928 solubilization Effects 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 210000002948 striated muscle cell Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
• 125000000542 sulfonic acid group Chemical group 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 230000007607 synaptic alteration Effects 0.000 description 1
• 210000002504 synaptic vesicle Anatomy 0.000 description 1
• 210000003568 synaptosome Anatomy 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
• 230000001732 thrombotic effect Effects 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 239000012096 transfection reagent Substances 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 229940078499 tricalcium phosphate Drugs 0.000 description 1
• 235000019731 tricalcium phosphate Nutrition 0.000 description 1
• 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• 108091005957 yellow fluorescent proteins Proteins 0.000 description 1